Ivacaftor (VX-770)

Ivacaftor (VX-770)は、G551D-CFTRとF508del-CFTRを目標としている嚢胞性線維症膜内外コンダクタンス監査機関(CFTR)の強化剤で、EC50 がそれぞれ 100 nM と 25 nMです。

価格 在庫  
USD 141 あり
USD 214 あり
USD 403 あり
USD 1222 あり

Ivacaftor (VX-770) 化学構造
分子量: 392.49



Quality Control & MSDS


  • Compare CFTR Inhibitors
  • 研究分野



製品説明 Ivacaftor (VX-770)は、G551D-CFTRとF508del-CFTRを目標としている嚢胞性線維症膜内外コンダクタンス監査機関(CFTR)の強化剤で、EC50 がそれぞれ 100 nM と 25 nMです。
ターゲット G551D-CFTR F508del-CFTR
IC50 100 nM 25 nM [1]
In vitro試験 Ivacaftor (10 μM) significantly increases the forskolin-stimulated Cl- secretion (IT) by ~4-fold with an EC50 of 100 nM in the recombinant Fisher rat thyroid (FRT) cells expressing G551D gating mutation of CFTR, and by ~6-fold with an EC50 of 25 nM in the recombinant cells expressing temperature-corrected F508del processing mutation of CFTR. Consistent with the increases in the forskolin-stimulated IT, Ivacaftor (10 μM) increases the open probability (Po) of G551D-, F508del-, and wild-type CFTR by ~6-fold, ~5-fold and ~2-fold, respectively, indicating that Ivacaftor acts directly on CFTR to increase its gating activity. In primary cultured human CF bronchial epithelia (HBE) carrying the G551D and F508del CFTR mutations, Ivacaftor (10 μM) potently increases the forskolin-stimulated IT by ~10-fold from 5% to a maximum level of 48% of that measured in non-CF HBE, with an EC50 of 236 nM displaying ~70-fold more potency compared with the commonly used CFTR potentiator genistein, which has an EC50 of 16 μM. In HBE with F508del homozygous CFTR, Ivacaftor causes a significant increase in the forskolin-stimulated IT with an EC50 of 22 nM, to a less extent from 4% to 16% of non-CF HBE compared with the effect in G551D/F508del HBE. Due to CFTR potentiation, Ivacaftor inhibits excessive ENaC-mediated Na+ and fluid absorption with an IC50 of 43 nM, and decreases the amiloride response, resulting in an increase in the surface fluid and cilia beat frequency (CBF) in G551D/F508del HBE. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HBE  NW\Qd5dNTnWwY4Tpc44hSXO|YYm= MoPoNVAh|ryP MUOxNEBucW5? NGHBWWtifWevZX70d{BETlSULXTldIVv\GWwdDDpc44hfHKjboPwc5J1yqB? NIfLcZAzPDFyNkiwNS=>
CFBE41o- M{GyXmZ2dmO2aX;uJGF{e2G7 MWSxNEDDvU1? NYDQb2o1cW6mdXPld{Bzd2K3c4SgbY5kemWjc3XzJIlvKGGwaX;uJJRz[W6|cH;yeC=> M{ewUFIzPzZ6MUOw
HBE  NFnpWW1HfW6ldHnvckBCe3OjeR?= NVnBXHpvOTBiwsXN M{HlZ4F2\22nboTzJGNHXFJvZHXw[Y5l\W62IHHubY9vKHS{YX7zdI9zfCCjY4Tpeol1gQ>? NEfPRYozOjd4OEGzNC=>
HBE  MU\GeY5kfGmxbjDBd5NigQ>? NYj2PIJPOTBiwsXN NVzWXYp2OjRiaB?= M2HReolv\HWlZYOgZUBud2Snc4SgZpV1KHOrZ37p[olk[W62IHnuZ5Jm[XOnIHnuJGFUVCCmZYD0bC=> MorqNlI4PjhzM{C=
HBE  NHrDSllHfW6ldHnvckBCe3OjeR?= MUKxNEDDvU1? MkXadI91\W62aXH0[ZMhS0[WUj3k[ZBmdmSnboSgTZNkNCC{ZXfhdoRt\XO|IH;mJJBzcW:{IHHkcYlvcXO2cnH0bY9vKG:oIFPTSS=> M1nROFIzPzZ6MUOw
HBE  M4jEe2Z2dmO2aX;uJGF{e2G7 MWqxNEDDvU1? NHrBRXlx[XK2aXHscJkhemW|dH;y[ZMh\GWybHX0bY9vKG:oIFHTUEBl\XC2aDDpckBEW0VidILlZZRm\CCvb37vcIF6\XK| NFX5N4MzOjd4OEGzNC=>

... Click to View More Cell Line Experimental Data

In vivo試験
臨床試験 A Phase III study of Ivacaftor in cystic fibrosis subjects age 6 to 11 with the G551D mutation has been completed.
特集 The first potent and orally available CFTR potentiator to enter human clinical trials.

プロトコル (参考用のみ)

キナーゼアッセイ: [1]

Ussing Chamber Recordings The effect of Ivacaftor on CFTR-mediated Cl- secretion is characterized by measuring the CFTR-mediated IT in chambers using recombinant Fisher rat thyroid (FRT) cells expressing G551D, or F508del CFTR. Cells are grown on Costar Snapwell cell culture inserts maintained at 37 °C before recording. The cell culture inserts are mounted into an Ussing chamber to record IT in the voltage-clamp mode (Vhold = 0 mV). For FRT cells, the basolateral membrane is permeabilized with 360 μg/mL Nystatin and a basolateral to apical Cl- gradient is established. The basolateral bath solution contains 135 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 0.6 mM KHPO4, 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (Hepes), and 10 mM dextrose (titrated to pH 7.4 with NaOH). The apical NaCl is replaced by equimolar Na+ gluconate (titrated to pH 7.4 with NaOH). The addition of a maximally effective concentration of forskolin (10 μM) is used to stimulate IT in the presence of various concentrations of Ivacaftor. All recordings are digitally acquired using Acquire and Analyze software. EC50 values are determined from the concentration-response curve of the increase in forskolin-stimulated IT after application of Ivacaftor.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)



Download Ivacaftor (VX-770) SDF
分子量 392.49


CAS No. 873054-44-5
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 78 mg/mL (198.73 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

文献中の引用 (10)



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related CFTR 化学物質

  • Elacridar (GF120918)

    Elacridar (GF120918) is a potent P-gp (MDR-1) and BCRP inhibitor.

  • Verdinexor (KPT-335)

    Verdinexor (KPT-335) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

  • Ataluren (PTC124)

    Ataluren (PTC124)は、~0.1μMのEC50による強力なナンセンス変異阻害剤です。

    Features:Demonstrates oral bioavailability, and an appropriate safety toxicology profile.

  • VX-809 (Lumacaftor)

    VX-809 (Lumacaftor)は、0.1μMのEC50による嚢胞性線維症膜内外コンダクタンス監査機関(CFTR)モジュレータです。

    Features:Higher specificity and efficacy relative to other CFTR defect drugs.

  • Lubiprostone

    Lubiprostone(Amitiza) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.

  • VX-661

    VX-661は、第F508del CFTR に補正され、CFTRタンパク質は細胞表面に達するのを助けると考えられている。

  • CFTRinh-172

    CFTRinh-172 is a voltage-independent, selective CFTR inhibitor with Ki of 300 nM, showing no effects on MDR1, ATP-sensitive K+ channels, or a series of other transporters.

  • IOWH032

    IOWH032 is a synthetic CFTR inhibitor. Phase 1/2.

  • Brefeldin A

    Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.


Tags: Ivacaftor (VX-770)を買う | Ivacaftor (VX-770)供給者 | Ivacaftor (VX-770)を購入する | Ivacaftor (VX-770)費用 | Ivacaftor (VX-770)生産者 | オーダーIvacaftor (VX-770) | Ivacaftor (VX-770)代理店
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID